This Month in JNM

Resurgence of immuno-PET: Wu provides an overview of the broad range of positron-emitting radionuclides and expanding spectrum of molecular targets under active investigation with novel combinations of antibodies and PET.
Page 2

Osteonecrosis of the jaw: Pazianas and colleagues offer cautionary perspectives on the causes, diagnosis, and management of osteonecrosis of the jaw and preview a related article in this issue of JNM.
Page 6

PET/CT after RIT: Jacene and colleagues report on a retrospective study of the utility of ¹⁸F-FDG PET/CT for monitoring responses to radioimmunotherapy in patients with non-Hodgkin lymphoma.
Page 8

SPECT/CT in DTC nodal staging: Schmidt and colleagues compare the diagnostic values of ¹³¹I SPECT/spiral CT and planar imaging in nodal staging at the first ablative therapy in differentiated thyroid carcinoma and discuss implications for patient management.
Page 18

PET/CT for HNSCC recurrence: Abgral and colleagues investigate the benefits of ¹⁸F-FDG PET/CT in detecting subclinical locoregional recurrence and distant metastases in patients one or more years after clinically curative treatment for head and neck squamous cell carcinoma.
Page 24

Jaw osteonecrosis and SPECT/CT: Dore and colleagues evaluate the diagnostic value added by SPECT/CT to conventional ^99mTc-methylene diphosphonate 3-phase bone scintigraphy in osteonecrosis of the jaw in bisphosphonate-treated patients.
Page 30

MRI and PET in glioma assessment: Swanson and colleagues explore the link between hypoxia and the proliferative and growth characteristics of glioblastoma multiforme by using MRI to assess spatial geometry and ¹⁸F-FMISO PET to assess hypoxia.
Page 36

Striatal DAT expression and genotype: van de Giessen and colleagues use SPECT to investigate correlations between polymorphisms in the dopamine transporter (DAT) gene and striatal DAT expression and review implications for research in neuropsychiatric disorders.
Page 45

Validating regional LV function assessment: Nichols and colleagues explore the correlation between global and regional left ventricular function by automated quantitative data from gated blood-pool SPECT and gated cardiac MRI and compare the results against visual assessments.
Page 53

Sympathetic nervous system and arrhythmia: Akutsu and colleagues evaluate the effectiveness of ¹²³I-MIBG scintigraphy of cardiac sympathetic nervous system abnormality as a predictor of sudden cardiac death during long-term follow-up in patients with histories of ventricular tachyarrhythmia.
Page 61

Repeatability of ⁸²Rb PET MBF measurements: Manabe and colleagues describe the short-term, same-day repeatability of ⁸²Rb PET rest and hyperemic myocardial blood flow results and discuss the possibilities for quantifying acute effects of therapeutic interventions.
Page 68

3D reconstruction algorithms for HRRT: van Velden and colleagues assess the accuracy of new iterative construction algorithms for reconstructing high-resolution research tomographic PET brain images.
Page 72

PET/CT and STIR MRI in lung cancer: Morikawa and colleagues compare the efficacies of separate and combined short-τ inversion-recovery MRI and ¹⁸F-FDG PET/CT in the detection of metastases in mediastinal and hilar lymph nodes in patients with lung cancer.
Page 81

PET and PET/CT in treatment response: Ben-Haim and Ell provide an educational review of the current status and applications of ¹⁸F-FDG imaging in monitoring responses to cancer treatment and describe the possibilities for enhancing personalized treatment strategies.
Page 88

4FMFES biodistribution and dosimetry: Beauregard and colleagues assess in healthy women the biodistribution, dosimetry, and safety of a newly developed radiolabeled estradiol analog for PET imaging of estrogen receptors.
Page 100

PET and P-gp function: Liow and colleagues describe the ability of ¹¹C-N-desmethyl-loperamide PET to quantify the function of P-glycoprotein at the blood–brain barrier in monkeys.
Page 108

Monitoring tumor vascularity change: Morrison and colleagues report on the favorable kinetics and tumor targeting properties of ¹⁸F-AH111585, a novel ¹⁸F-RGD peptide, and on its ability to noninvasively assess tumor vascularity.
Page 116

Quantifying cetuximab uptake: Aerts and colleagues describe the development and validation of an ⁸⁹Zr-labeled monoclonal antibody probe for PET imaging, with the potential for enhancing patient selection for treatment and tailoring cetuximab dosage to individual needs.
Page 123

PET and LV function in mice: Stegger and colleagues detail a novel method for quantifying left ventricular volume and ejection fraction in mice, thereby combining molecular and functional cardiac imaging in a single research scan.
Page 132

Inveon resolution and sensitivity: Visser and colleagues examine the whole-field-of-view resolution and sensitivity of the Inveon small-animal PET scanner and identify optimal reconstruction techniques.
Page 139

PET for intratumoral inhomogeneity: Shiga and colleague describe the development and validation of a new CdTe semiconductor detector–based clinical PET system that provides images with high spatial resolution and low scatter noise.
Page 148

USP <797> and Mayo pharmacy remodeling: Hung and Anderson review the appropriateness and effectiveness of their institution's approaches to meeting new U.S. Pharmacopeia requirements to minimize airborne contamination from radiopharmaceutical compounding facilities.
Page 156

ON THE COVER

In non-Hodgkin lymphoma, ¹⁸F-FDG uptake in tumors typically drops after radioimmunotherapy, with the largest declines occurring in those with the longest progression-free survival. This patient, whose baseline PET/CT scan (top) and follow-up scans at 12 wk (middle) and 24 wk (bottom) showed a gradual decline in the size and metabolic activity of lymph nodes, remained without evidence of active disease 28 mo after radioimmunotherapy.

See page 15.